Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

Gebruikersavatar
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1632
Lid geworden op: 17 sep 2014 14:20
waarderingen: 688
Contacteer:

Re: Sorrento therapeutics

Bericht door Munnybunny »

Brazil Healthcare Regulator Authorizes Sorrento Therapeutics' Phase 2 Trial for Coronavirus Drug Candidate
The American biotech aims to recruit 400 people for the study.

Abivertinib, one of Sorrento Therapeutics' (NASDAQ:SRNE) COVID-19 drug candidates, will be entering phase 2 testing in Brazil. This follows approval granted on Wednesday by the National Health Surveillance Agency (ANVISA), the country's healthcare regulator, which has cleared the U.S. company to advance the drug's development in the sprawling South American nation.

Abivertinib was originally designed to treat cancer; Sorrento believes it can limit the overactive immune systems seen in some COVID-19 patients.

In July, the drug was cleared for phase 2 testing in the U.S., but the Brazil study will have several differences. Among other distinctions, it will involve patients with mild, moderate, or severe forms of the illness; participants in the American trial are limited to severe COVID-19 cases. In Brazil, any hospitalized patient will be eligible; patients in the U.S. study must be in the intensive care unit and nonventilated.

A medical professional using a microscope.
IMAGE SOURCE: GETTY IMAGES.

All told, Sorrento aims to recruit 400 participants in the Brazil trial. It says that its partnerships with local organizations and medical systems in the country should help it enroll that number quickly.

Testing Abivertinib on a population outside the so-called "first world" is intentional.

"By targeting some of the geographies currently most impacted by COVID-19, we are able to implement a synergistic program to answer questions about safety and efficacy of our drug candidates in helping patients, while potentially accelerating enrollment timelines, reducing overall cost and opening up collaboration opportunities with local companies," Sorrento quoted CEO Henry Ji as saying.

The company is one of numerous biotechs around the world engaged in the fight against COVID-19; Abivertinib is among a clutch of drugs and vaccines Sorrento is trying to develop for this purpose.







Volg Beursig.com op Twitter en Facebook


believer
Forum elite
Forum elite
Berichten: 4930
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4303
Contacteer:

Re: Sorrento therapeutics

Bericht door believer »

Erg voor de bevolking,zeer goed voor Sorrento

https://www.hln.be/medisch/who-deelt-te ... ~af1fe9f6/

Haussier
Forum newbie
Forum newbie
Berichten: 6
Lid geworden op: 12 aug 2020 11:46
waarderingen: 2
Contacteer:

Re: Sorrento therapeutics

Bericht door Haussier »

... Als er nog iemand met enige logische verklaring kan komen voor deze koersen, ik hoor het graag.
Ik dacht dat na de R&D-conferentie de lucht uit het aandeel zou zijn...

alwaysright
Forum actieveling
Forum actieveling
Berichten: 920
Lid geworden op: 10 mei 2013 19:25
waarderingen: 361
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

We zijn op het ogenblik gewoon toeschouwers.....en zien de hedges funds aan het werk.
Toch blijf ik rustig zitten,komt gewoon goed.

strever
Forum actieveling
Forum actieveling
Berichten: 734
Lid geworden op: 04 jan 2015 14:33
waarderingen: 221
Contacteer:

Re: Sorrento therapeutics

Bericht door strever »

Ik vrees dat die sneltest niet voor direct is!
!!!!Ben ik nu zo slim of is een ander zo dom?

ancaoli
Forum veteraan
Forum veteraan
Berichten: 1701
Lid geworden op: 28 jan 2018 18:54
waarderingen: 887
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

Waar ze wel goed in zijn zijn overnames. Hoe kunnen ze dit blijven bolwerken??

Sorrento Therapeutics (SRNE) to purchase ACEA Therapeutics

October 16, 2020 4:35 PM
Sorrento Therapeutics (NASDAQ: SRNE) disclosed:

On October 14, 2020, Sorrento Therapeutics, Inc. (“Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) entered into a binding term sheet (the “Binding Term Sheet”) setting forth the terms and conditions by which Sorrento will, through a subsidiary, purchase all of the issued and outstanding equity of ACEA (the “Acquisition”). Contingent upon the execution of a definitive agreement between the parties (the “Definitive Agreement”) and subject to certain conditions, Sorrento will, at the closing of the Acquisition (the “Closing”), make an initial payment of $38,000,000, subject to certain adjustments (the “Initial Consideration”).


In addition to the Initial Consideration, Sorrento shall issue contingent value rights to the equityholders of ACEA representing the right to receive the following payments: (i) the amounts that would otherwise be due to ACEA under that certain License Agreement, dated July 13, 2020 (the “License Agreement”), between Sorrento and ACEA (as previously disclosed in Sorrento’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2020), (ii) with respect to specified royalty-bearing products, five percent of the annual net sales thereof in a manner consistent with the royalty payment terms of the License Agreement, and (iii) up to $265,000,000 in additional payments, subject to the receipt of certain regulatory approvals and achievement of certain net sales targets with respect to the assets acquired pursuant to the Acquisition.

Under the Binding Term Sheet, ACEA has agreed to negotiate exclusively with Sorrento with respect to the Acquisition for a period of 90 days.

The final terms of the Acquisition are subject to the negotiation and finalization of the Definitive Agreement and any other agreements relating to the Acquisition, and the material terms of the Acquisition may differ from those set forth in the Binding Term Sheet. In addition, the Closing will be subject to various customary and other closing conditions, including the approval of ACEA’s equityholders.

The foregoing description of terms of the Binding Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the (i) Binding Term Sheet that will be filed with the Securities and Exchange Commission as an exhibit to an amendment to this Current Report on Form 8-K or to Sorrento’s Annual Report on Form 10-K for the fiscal year ending December 31, 2020, and (ii) the License Agreement that will be filed with the Securities and Exchange Commission as an exhibit to Sorrento’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 780
Lid geworden op: 25 dec 2013 21:48
waarderingen: 251
Contacteer:

Re: Sorrento therapeutics

Bericht door Stefkamielkafkajr »

ancaoli schreef:
16 okt 2020 23:56
Waar ze wel goed in zijn zijn overnames. Hoe kunnen ze dit blijven bolwerken??

Sorrento Therapeutics (SRNE) to purchase ACEA Therapeutics

October 16, 2020 4:35 PM
Sorrento Therapeutics (NASDAQ: SRNE) disclosed:

On October 14, 2020, Sorrento Therapeutics, Inc. (“Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) entered into a binding term sheet (the “Binding Term Sheet”) setting forth the terms and conditions by which Sorrento will, through a subsidiary, purchase all of the issued and outstanding equity of ACEA (the “Acquisition”). Contingent upon the execution of a definitive agreement between the parties (the “Definitive Agreement”) and subject to certain conditions, Sorrento will, at the closing of the Acquisition (the “Closing”), make an initial payment of $38,000,000, subject to certain adjustments (the “Initial Consideration”).


In addition to the Initial Consideration, Sorrento shall issue contingent value rights to the equityholders of ACEA representing the right to receive the following payments: (i) the amounts that would otherwise be due to ACEA under that certain License Agreement, dated July 13, 2020 (the “License Agreement”), between Sorrento and ACEA (as previously disclosed in Sorrento’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2020), (ii) with respect to specified royalty-bearing products, five percent of the annual net sales thereof in a manner consistent with the royalty payment terms of the License Agreement, and (iii) up to $265,000,000 in additional payments, subject to the receipt of certain regulatory approvals and achievement of certain net sales targets with respect to the assets acquired pursuant to the Acquisition.

Under the Binding Term Sheet, ACEA has agreed to negotiate exclusively with Sorrento with respect to the Acquisition for a period of 90 days.

The final terms of the Acquisition are subject to the negotiation and finalization of the Definitive Agreement and any other agreements relating to the Acquisition, and the material terms of the Acquisition may differ from those set forth in the Binding Term Sheet. In addition, the Closing will be subject to various customary and other closing conditions, including the approval of ACEA’s equityholders.

The foregoing description of terms of the Binding Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the (i) Binding Term Sheet that will be filed with the Securities and Exchange Commission as an exhibit to an amendment to this Current Report on Form 8-K or to Sorrento’s Annual Report on Form 10-K for the fiscal year ending December 31, 2020, and (ii) the License Agreement that will be filed with the Securities and Exchange Commission as an exhibit to Sorrento’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.
inderdaad ze blijven overnames doen in de marge
der moet toch een of andere manier zijn om de banken te kunnen overtuigen voor die overnames de financieren
Altice europe,aegon,, euronav, acacia pharma,fagron,,, greenyard ,pharming, , econocom.Xfab.oxurion.sorrento therapeutics.luckin coffe adr

alwaysright
Forum actieveling
Forum actieveling
Berichten: 920
Lid geworden op: 10 mei 2013 19:25
waarderingen: 361
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Ik heb die site eens even bekeken van ACEA en wat het eerste is dat opvalt is dat het allemaal Chinezen zijn die daar de zaak runnen.Verder zie je dat ze een partnership hebben met Eli Lilly en dat ze een gemeenschappelijke deler hebben met Abivertinib.Ik hoop niet dat dit uitdraait op een verkapte kapitaalsverhoging,want zoals al gezegd....waar halen ze de centen vandaan?

ancaoli
Forum veteraan
Forum veteraan
Berichten: 1701
Lid geworden op: 28 jan 2018 18:54
waarderingen: 887
Contacteer:

Re: Sorrento therapeutics

Bericht door ancaoli »

alwaysright schreef:
17 okt 2020 12:37
Ik heb die site eens even bekeken van ACEA en wat het eerste is dat opvalt is dat het allemaal Chinezen zijn die daar de zaak runnen.Verder zie je dat ze een partnership hebben met Eli Lilly en dat ze een gemeenschappelijke deler hebben met Abivertinib.Ik hoop niet dat dit uitdraait op een verkapte kapitaalsverhoging,want zoals al gezegd....waar halen ze de centen vandaan?
Centen krijgen ze gemakkelijk binnen via ATM regeling; ik dacht dat ze voor 250 of zelfs 400 miljoen $ regelmatig aandelen in de markt verkopen. Daarmee zijn de andere overnames en terugbetaalde lening waarschijnlijk gefinancierd. TBC
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Argenx, Agfa, Ontex, OCI, Sorrento, Inventiva

alwaysright
Forum actieveling
Forum actieveling
Berichten: 920
Lid geworden op: 10 mei 2013 19:25
waarderingen: 361
Contacteer:

Re: Sorrento therapeutics

Bericht door alwaysright »

Ik dacht het maximaal 250 miljoen was.


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie